What is the largest pharmaceutical company in Switzerland?

What is the largest pharmaceutical company in Switzerland?

Two of the world’s leading pharmaceutical companies, Novartis and Roche, call Switzerland home.

How many pharmaceutical companies are there in Switzerland?

With over 250 pharmaceutical and biotechnology companies based across Basel, Zurich, Geneva and other core cities in Switzerland, there is already a proven and well-resourced access to talent, resources, funding and clinical development within the country.

Why Switzerland has so many pharmaceutical companies?

Switzerland is known for providing bespoke pharmaceutical solutions through its access to and funding for intensive research and development of these fine chemicals. The global demand for these speciality chemicals is always increasing, which makes Switzerland’s assets valuable.

How many biotech companies are there in Switzerland?

314 biotech companies
There are 314 biotech companies in Switzerland: broken down into 251 developers and 63 suppliers. Swiss life science exports were valued at CHF 99.1bn ($108bn USD) in 2020 and accounted for 44% of total exports.

What pharmaceutical companies are in Basel?

Companies

  • Hoffmann-La Roche: Basel.
  • Novartis: Basel.
  • Alcon: Geneva.
  • Bayer: Basel (Consumer Health Division, Hemophilia & Ophthalmology Pharma Global HQ Divisions with some Oncology)
  • Lonza Group: Basel.
  • Abbott: Basel (Established Pharmaceuticals Division)
  • Galenica: Bern.
  • Actelion (Johnson & Johnson): Basel.

Where is Roche located in Switzerland?

Basel, Switzerland
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide.

Is Switzerland Good for biotechnology?

Switzerland is one of the best and most innovative locations for biotechnology in Europe. Local companies hold leading positions throughout many sectors and thus attract capital and researchers from all over the world. Switzerland offers an outstanding framework for procuring capital.

author

Back to Top